Dergiler / Turkish Journal of Biology / 2021 / Cilt: 45 - Sayı: 4

Pathogenesis and treatment of cytokine storm in COVID-19

Sayfa
372–389
Yayın Tarihi
2022-10-17
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Currently corticosteroids, IL-6 blockers, or IL-1 blockers are most widely used for treating COVID-CS.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:COVID-19 is a viral infection caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that killed a large number of patients around the world.
📊
Temel Bulgular & Veri:Many mechanisms have been suggested in the pathogenesis of COVID-19 associated cytokine storm (COVID-CS).
💡
Sonuç & Katkı:Currently corticosteroids, IL-6 blockers, or IL-1 blockers are most widely used for treating COVID-CS.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

COVID-19 is a viral infection caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that killed a large number of patients around the world. A hyperinflammatory state resulting in a cytokine storm and adult respiratory distress syndrome seems to be the major cause of the death. Many mechanisms have been suggested in the pathogenesis of COVID-19 associated cytokine storm (COVID-CS). Insufficient viral clearance and persistence of a strong cytokine response despite inadequate antiviral immunity seem to be the main mechanisms underlying the pathogenesis. The diagnosis of COVID-19 is based on relatively constant clinical symptoms, clinical findings, laboratory tests, and imaging techniques, while the diagnosis of COVID-CS is a rather dynamic process, based on evolving or newly emerging findings during the clinical course. Management of COVID-19 consists of using antiviral agents to inhibit SARS-CoV-2 replication and treating potential complications including the cytokine storm together with general supportive measures. COVID-CS may be treated using appropriate immunosuppressive and immunomodulatory drugs that reduce the level of inappropriate systemic inflammation, which has the potential to cause organ damage. Currently corticosteroids, IL-6 blockers, or IL-1 blockers are most widely used for treating COVID-CS.

🔖

Bu Makaleye Atıf Yap

KESER, G., ATAGÜNDÜZ, P., SOY, M. (2022). Pathogenesis and treatment of cytokine storm in COVID-19. Turkish Journal of Biology, Cilt: 45 - Sayı: 4, 372–389. https://ajindex.com/articles/600145

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (3)

  1. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF (2020). The proximal origin of SARS-CoV-2. Nature Medicine 26 (4): 450-452. doi: 10.1038/s41591-020-0820-9
  2. Baghaei P, Dastan F, Marjani M, Moniri A, Abtahian Z et al. (2021). Combination therapy of IFNβ1 with lopinavir– ritonavir, increases oxygenation, survival and discharging of sever COVID-19 infected inpatients. International Immunopharmacology 92: 107329. doi: 10.1016/j. intimp.2020.107329 Barrat FJ, Elkon KB, Fitzgerald KA (2016). Importance of nucleic acid recognition in inflammation and autoimmunity. Annual Review of Medicine 67 (1): 323-336. doi: 10.1146/annurevmed-052814-023338
  3. Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH et al. (2020). Autoantibodies against type I IFNs in patients with lifethreatening COVID-19. Science 370 (6515): eabd4585. doi: 10.1126/science.abd4585 Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I et al. (2020). COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. Journal of the American College of Cardiology 75 (23): 2950-2973. doi: 10.1016/j.jacc.2020.04.031 Bourgonje AR, Abdulle AE, Timens W, Hillebrands JL, Navis GJ et al. (2020). Angiotensin‐converting enzyme 2 (ACE2), SARS‐ CoV‐2 and the pathophysiology of coronavirus disease 2019 (COVID‐19). The Journal of Pathology 251 (3): 228-248. doi: 10.1002/path.5471 Brenner EJ, Ungaro RC, Gearry RB, Kaplan GG, Kissous-hunt M et al. (2020). Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry. Gastroenterology 159 (2): 481-491.e3. doi: 10.1053/j. gastro.2020.05.032 Campochiaro C, Della-torre E, Cavalli G, De Luca G, Ripa M et al. (2020). Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. European Journal of Internal Medicine 76: 43-49. doi: 10.1016/j. ejim.2020.05.021 Cantini F, Niccoli L, Nannini C, Matarrese D, Natale MED et al. (2020). Beneficial impact of baricitinib in COVID-19 moderate pneumonia; multicentre study. Journal of Infection 81 (4): 647- 679. doi: 10.1016/j.jinf.2020.06.052 Cao W, Liu X, Bai T, Fan H, Hong K et al. (2020b). High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019. Open Forum Infectious Diseases 7 (3). doi: 10.1093/ofid/ofaa102 Cao Y, Wei J, Zou L, Jiang T, Wang G et al. (2020